Ascentage Pharma recently unveiled promising clinical data on the use of Alrizomadlin as a monotherapy and in combination therapies for solid tumors at ASCO 2025. The presentation highlighted the company’s optimistic outlook and strategic plans for future developments in the pharmaceutical industry. Ascentage Pharma’s forward-looking statements, as per the regulations, express the company’s views on […]